An Overview of the “Visionary” Study: A Phase 3 Trial of Sibeprenlimab for IgA Nephropathy

Time: 4:30 pm
day: Day One

Details:

  • Explore the current approach to IgAN treatment
  • Understand the need for new therapies for IgAN
  • Examine the role of the APRIL pathway in the pathogenesis of IgAN

Speakers: